Circassia Builds US Respiratory Presence with AstraZeneca Deal
Circassia has put memories of last year's Cat-SPIRE disappointment firmly behind it with a new deal with AstraZeneca for Tudorza and Duaklir in COPD that will allow it to concentrate on boosting its respiratory franchise.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
In its continuing efforts to diversify away from opioid pain drugs, Purdue partners on non-opioid program with Alivio. Rigel licenses Tavalisse rights in all indications go to Spain’s Grifols.
UK group Mereo BioPharma is paying a very reasonable $5m to get its hands on AstraZeneca’s Phase II compound for the rare genetic disorder AATD.